Characteristics | Allb | Protein expression | All | mRNA expressionc | All | DNA methylationd | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low n (%) | High n (%) | Low n (%) | High n (%) | Low n (%) | High n (%) | ||||||||
Overall | 76 | 67 (88.2) | 9 (11.8) | 52 | 26 (50.0) | 26 (50.0) | 101 | 46 (8.9) | 55 (54.5) | ||||
Tumor type | |||||||||||||
IDC | 60 | 52 (86.7) | 8 (13.3) | 52 | 26 (50.0) | 26 (50.0) | 98 | 43 (43.9) | 55 (56.1) | ||||
ILC | 1 | 1 (100.0) | 0 (0.0) | 0 | 0 (0.0) | 0 (0.0) | 2 | 2 (100.0) | 0 (0.0) | ||||
Others | 5 | 5 (100.0) | 0 (0.0) | 0 | 0 (0.0) | 0 (0.0) | 1 | 1 (100.0) | 0 (0.0) | ||||
Tumor stage | |||||||||||||
0, I and II | 48 | 41 (85.4) | 7 (14.6) | 9 | 5 (55.6) | 4 (44.4) | 19 | 7 (36.8) | 12 (63.2) | ||||
III and IV | 18 | 17 (94.4) | 1 (5.6) | 41 | 21 (51.2) | 20 (48.8) | 79 | 38 (48.1) | 41 (51.9) | ||||
Tumor size | |||||||||||||
T0–T1 | 11 | 10 (90.9) | 1 (9.1) | 40 | 24 (60.0) | 16 (40.0)0.040 | 30 | 12 (40.0) | 28 (60.0) | ||||
T2–T4 | 52 | 46 (88.5) | 6 (11.5) | 9 | 2 (22.2) | 7 (77.8) | 68 | 33 (48.5) | 35 (51.5) | ||||
Lymph node regional metastasis | |||||||||||||
No | 27 | 25 (92.6) | 2 (7.4) | 23 | 14 (60.9) | 9 (39.1) | 43 | 21 (48.8) | 22 (51.2) | ||||
Yes | 36 | 31 (86.1) | 5 (13.9) | 25 | 11 (44.0) | 14 (56.0) | 51 | 24 (47.1) | 27 (52.9) | ||||
Grade | |||||||||||||
Well | 4 | 3 (75.0) | 1 (25.0) | 7 | 3 (42.9) | 4 (57.1) 7 | 10 | 5 (50.0) | 5 (50.0) | ||||
Moderate | 27 | 22 (81.5) | 5 (18.5) | 17 | 9 (52.9) | 8 (47.1) | 40 | 17 (42.5) | 23 (57.5) | ||||
Poor | 29 | 27 (93.1) | 2 (6.9) | 24 | 13 (54.2) | 11 (45.8) | 42 | 20 (47.6) | 22 (52.4) | ||||
ER | |||||||||||||
Negative | 39 | 35 (89.7) | 4 (10.0) | 15 | 8 (53.3) | 7 (46.7) | 31 | 14 (45.2) | 17 (54.8) | ||||
Positive | 37 | 32 (86.5) | 5 (13.5) | 27 | 13 (48.1) | 14 (51.9) | 68 | 30 (44.1) | 38 (55.9) | ||||
PR | |||||||||||||
Negative | 42 | 39 (92.9) | 3 (7.1) | 16 | 9 (56.3) | 7 (43.8) | 40 | 16 (40.0) | 24 (60.0) | ||||
Positive | 34 | 28 (82.4) | 6 (17.6) | 26 | 12 (46.2) | 14 (53.8) | 59 | 28 (47.5) | 31 (52.5) | ||||
HER2 | |||||||||||||
Negative | 42 | 51 (92.7) | 4 (7.3)0.046 | 18 | 10 (55.6) | 8 (44.4) | 39 | 18 (46.2) | 21 (53.8) | ||||
Positive | 21 | 16 (76.2) | 5 (23.8) | 22 | 20 (45.5) | 3 (54.5) | 59 | 25 (42.4) | 34 (57.6) | ||||
TNBC | |||||||||||||
Yes | 23 | 22 (95.7) | 1 (4.3) | 10 | 5 (50.0) | 5 (50.0) | 15 | 6 (40.0) | 9 (60.0) | ||||
No | 53 | 45 (84.9) | 8 (15.1) | 32 | 16 (50.0) | 16 (50.0) | 84 | 38 (45.2) | 46 (54.8) | ||||
Ki-67 | |||||||||||||
< 14% | 10 | 9 (90.0) | 1 (10.0) | 11 | 5 (45.5) | 6 (54.5) | 26 | 13 (50.0) | 13 (50.0) | ||||
≧14% | 16 | 11 (68.8) | 5 (31.3) | 23 | 10 (43.5) | 13 (56.5) | 66 | 27 (40.9) | 39 (59.1) | ||||
p53 | |||||||||||||
Negative | 26 | 26 (100.0) | 0 (0.0) | ||||||||||
Positive | 22 (88.0) | 3 (12.0) |